In a study that compared the sensitivity of three different NSCLC cell lines to EGCG, resistance to treatment was observed for two cell lines harboring mutations in EGFR, indicating a strong association between the anticancer activity of EGCG and EGFR mutation status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.